Polatuzumab Vedotin-Piiq Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Polatuzumab Vedotin-Piiq Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Approved
Highest phase
107
Registered trials
154
Result records
1
Matched deals
Executive recommendation: GO
Decision memo
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
The central underwriting question is whether Polatuzumab Vedotin-Piiq can convert its Antibody drug conjugate (ADC) profile and CD79B x Tubulin biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Polatuzumab Vedotin-Piiq (query alias: polatuzumab vedotin) |
|---|---|
| Modality / target | Antibody drug conjugate (ADC); CD79B x Tubulin; CD79B inhibitors, Tubulin inhibitors |
| Highest global status | Approved |
| Originator | GeneTech, Inc. |
| Active developers | F. Hoffmann-La Roche Ltd., Genentech, Inc., Hoffmann-La Roche, Inc. |
The MCP disease footprint includes Large B-cell lymphoma, High grade B-cell lymphoma, Diffuse large B-cell lymphoma refractory. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| NCT07677813 | Phase 2 | Not yet recruiting | 66 | 2year PFS |
| NCT07654426 | Phase 2 | Not yet recruiting | 60 | Left Ventricular Ejection Fraction (LVEF) |
| NCT07702851 | Phase 2 | Not yet recruiting | 47 | Complete response rate at the end of treatment |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
Comparative real-world safety outcomes of Pola-R-CHP versus R-CHOP in high-grade diffuse large B-cell lymphoma (DLBCL): A TriNetX study.
Not Applicable; n=19327; evaluation: Positive. Reported fields: all-cause mortality(1-year) = 13.3 % ; all-cause mortality(1-year) = 7.0 %
MULTIVARIABLE ANALYSES OF OVERALL SURVIVAL IN THE PHASE 3 SUNMO, STARGLO AND POLARGO TRIALS IN RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA
Phase 3; n=1403; evaluation: Positive. Reported fields: OS: HR = 0.65(95.0% CI, 0.41 - 1.02); HR = 0.59(95.0% CI, 0.44 - 0.81); HR = 0.62(95.0% CI, 0.48 - 0.81); OS: HR = 0.65(95.0% CI, 0.41 - 1.02); HR = 0.59(95.0% CI, 0.44 - 0.81); HR = 0.62(95.0% CI, 0.48 - 0.81); OS: HR = 0.65(95.0% CI, 0.41 - 1.02); HR = 0.59(95.0% CI, 0.44 - 0.81); HR = 0.62(95.0% CI, 0.48 - 0.81)
MOSUNETUZUMAB PLUS POLATUZUMAB VEDOTIN VERSUS RITUXIMAB, GEMCITABINE AND OXALIPLATIN IN LARGE B-CELL LYMPHOMA: UPDATED EFFICACY AND SAFETY FROM THE PHASE 3 SUNMO STUDY INCLUDING IN PATIENT SUBGROUPS
Phase 3; n=208; evaluation: Positive. Reported fields: ORR = 66.2 % ; ORR = 36.7 % ; ORR = 42.5 %
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Polatuzumab Vedotin-Piiq addresses Large B-cell lymphoma, High grade B-cell lymphoma, Diffuse large B-cell lymphoma refractory. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Antibody drug conjugate (ADC)—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The strongest market-validation signal in this screen is partner behavior: 1 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.
5. Transaction precedent and economics
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2012-10-10 | Seattle Genetics Achieves Milestones as Genentech Advances Two Antibody-Drug Conjugates (ADCs) into Phase II Development | Not disclosed | Financial terms not disclosed |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
The milestone feed surfaced a patent-application signal described as “Subcutaneous dosing of mosunetuzumab in combination with polatuzumab vedotin for use in treating non-hodgkin's lymphoma”.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.
7. Principal risks and diligence gates
- CLDN18.2 assay, cutoff, and intratumoral heterogeneity
- Payload-related toxicity and dose intensity
- Crowding from antibodies, bispecifics, CAR-Ts, and competing ADCs
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
GO
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 15 July 2026. Counts and status fields may change as source records update.
